LCGC North America
In advance of Pittcon 2018, leading scientists-Ronald Majors, Richard Henry, John W. Dolan, Zachary S. Breitbach, and Daniel W. Armstrong-who will be speaking at the LCGC awards symposium give us a preview of their talks.
In advance of Pittcon 2018, leading scientist Ronald Majors, who will be speaking at the LCGC awards symposium, gives us a preview of his talk.
The column has always played a pivotal role in the capability of liquid chromatography (LC) to solve "real world" problems. From the early days of large particle superficially porous packings (SPPs) to the eventual decades of domination of 5-µm reversed-phase columns to today's modern monolithic, sub-2-µm porous and the (revisited) small-particle SPPs, the state of column technology has often led, and sometimes fallen behind, the capabilities of the instrumentation that it supports. My presentation at the conference will highlight the developments in high performance liquid chromatography (HPLC) (and the newer term ultrahigh-pressure liquid chromatography [UHPLC]) columns that have brought liquid-phase separations to an elevated level of contribution to the analytical laboratory. We will also look into our crystal ball and delve into possible future directions in column technology.
The birth year of HPLC is generally recognized as 1966 (1). Then, microparticulate ion-exchange resins (10 µm diameter), SPP (45–60 µm), and flow-through ultraviolet (UV) detector development capped a year of discovery. To follow these and future developments, Figure 1 shows pivotal events in the development of column particle technology from the early 1960s onward. For most practitioners, the development of SPPs was a breakthrough since separations previously performed on large porous silica particles could now be accomplished in a fraction of the time. The SPPs were rather large, consisting of a glass bead or solid-core silica as the base material and a thin porous layer (thickness 1–2 µm) as the separation media. Relative to the larger (greater than 100 µm), totally porous particle (TPP), column efficiencies were quite good, but the low surface area limited the sample capacity of the packed column. The improvement in efficiency was because of the short diffusion pathlength in this thin porous layer. Nevertheless, in the early 1970s, SPPs were the rage. They could be dry-packed by the user much like a packed gas chromatography (GC) column of the day.
Another critical development in the early 1970s was the advent of bonded stationary phases. The older coated phases were very unstable and frequently stripped off the surface of the SPP. The mobile phase had to be saturated with dissolved stationary phase, which was very inconvenient and almost impossible to run any type of gradient elution. The bonded phases (monomeric and polymeric) allowed the use of more-polar solvents and gave way to the development of reversed-phase chromatography, which eventually came to dominate the mode usage and carries on today.
It had long been known, based on the decades earlier work of Martin and Synge (2), that "the smallest HETP (height equivalent to a theoretical plate) should be obtainable by using very small particles and a high-pressure differential across the length of the column." In the late 1960s, there were no sub-10-µm silica particles available-that is, until E. Merck (Darmstadt, Germany) was able to fractionate their irregularly shaped, thin-layer-grade silica into smaller particle sizes. Using a balanced density slurry procedure (slurry packing techniques are still used today), stable and reproducible silica gel columns were packed with 5–10 µm particles and demonstrated much higher efficiencies than the SPP columns (3). Figure 2 shows the first chromatogram obtained with a synthetic mixture in 1971 (3). This chromatogram looked pretty good, even by today's standards. After the 1971 commercialization of sub-10-µm TPP columns, the developments in column technology took off with spherical porous silica particles, a wide variety of siloxane bonded phases for several modes of HPLC, wide-pore packings for biomolecules being matched by the development of high-pressure HPLC instrumentation, and a variety of detectors and data systems that could quickly measure peak areas, retention times, and provide easy-to-read chromatographic outputs.
Referring again to Figure 1, as the years rolled on, the particle size of HPLC packings continued to decrease each time resulting in a doubling of column efficiency and speed. Speed was enhanced by the proportional decrease in column length to maintain the same efficiency.
Figure 1: History of commercial HPLC particle development.
For most of the 1980s and into the 1990s, workers seemed to be content with the use of 5-µm TPP columns (Figure 3a) and instruments capable of 400-bar operation. Smaller particle size nonporous-resins and silicas came about, but because of very low sample capacity and frequent pressure problems they quickly fell by the wayside. Gradually, 3–3.5 µm particles found use in some analytical laboratories but in the new millennium, 1.8-µm packed columns (subset of Figure 3a) were introduced, accompanied by a new range of instrumentation with a new generation of pumps to work with these higher-pressure columns. The pressure race was on. However, narrower peaks and the anticipation that TPP sizes would continue to decrease led manufacturers to also focus on smaller extracolumn volumes to handle the narrower peaks from these columns. The resultant technique became UHPLC, which implied that chromatographers had to upgrade their existing instruments to perform better with these columns.
Figure 2: First successfully packed HPLC column using microparticulate (5–10 µm) silica, circa 1971 (3). Column: 15 cm × 2.1 mm; mobile phase: n-hexane; flow rate: 400 mL/h; detection: UV absorbance; temperature: ambient; sample: 4 µL of mixture of ~1 mg/mL of each component. Peaks: 1 = impurity, 2 = phenetole, 3 = nitrobenzene, 4 = methyl benzoate, 5 = carbazole, 6 = acetophenone, 7 = 2,4-dinitrobenzene.
Note from Figure 1, that along the way, the concept of SPPs resurfaced, mainly driven by the work of the late J.J. Kirkland (4), who was a proponent of SPP in the early days. However, this time the size of the solid-core material was more than an order of magnitude smaller than the SPPs of the 1960s. The shell was thinner. There were also some new particle names: fused-core, core–shell, solid-core, and Poroshell, to name a few. Kirkland's SPP introduction was for the high-speed separation of large biomolecules such as proteins. Because of their size, proteins diffuse very slowly in solution, with about 10 times lower diffusion coefficients than those typical of small molecules. Therefore, as shown in Figure 3b, the short diffusion pathlength of the wide-pore packing brought about many advantages compared to totally porous particles of the same size, allowing large molecules to diffuse into and out of this thin layer very quickly, even at relatively high flow rates, thereby improving mass transfer kinetics. The larger 300-Å pore size was large enough to accommodate proteins up to 500 kDa.
Figure 3: Comparison of various particle types: (a) 5-µm totally porous particle (TPP), (b) 5-µm superficially porous particle (SPP), and (c) 2.7-µm SPP.
However, the biggest breakthrough for small-molecule separations came in the late 2000s when Kirkland once again brought the SPP technology to the forefront (5). By their introduction, the sub-3-µm SPP particles generated a significant interest in the chromatographic community. A typical example of the profile of a 2.7-µm SPP particle is shown in Figure 3c. This configuration has a 1.7-µm solid core with a 0.5-µm silica shell and 120-Å pores. These particles gave rise to column efficiencies rivaling the sub-2-µm TPP but, because of their 2.7-µm particle size, the pressure drop for the same size column was approximately 40–50% lower. Thus, in addition to the higher-pressure UHPLC instruments, most SPP columns of this particle size can be used with some of the conventional 400-bar HPLC systems. Longer columns can be used to generate more theoretical plates with UHPLC systems for more difficult separations. The number of sub-3-µm commercial SPP products took off like a rocket, and they appear to be replacing the sub-2-µm TPP, albeit with much lower operating pressures while operating at the same efficiency with only a slightly reduced sample capacity. Even smaller SPP columns (down to 1.3 µm) are now available. Needless to say, SPPs are here to stay and hardly a whisper is heard about sub-2-µm TPPs. A comparison of the two types of columns is shown in Figure 4.
Figure 4: Isocratic separation of alkylphenones on (a) a totally porous particle column and (b) a superficially porous particle column. Column: (a) 50 mm × 4.6 mm, 1.8-µm Zorbax Eclipse Plus C18, (b) 50 mm × 4.6 mm, 2.7-µm Poroshell 120; pressure: (a) 358 bar, (b) 220 bar; mobile phase: 60:40 acetonitrile–water; flow rate: 2.5 mL/min. Peaks: 1 = uracil, 2 = acetanilide, 3 = acetophenone, 4 = propiophenone, 5 = butyrophenone, 6 = benzophenone, 7 = valerophenone, 8 = hexanophenone, 9 = heptanophenone, 10 = octanophenone.
One other current column type will be addressed: Where do monolithic columns fit into the chromatography laboratory? Although monoliths have been around for more than two decades, they have not come close to replacing microparticulate columns. Research continues to provide improved performance for both silica- and polymer-based monoliths. So, they shouldn't be counted out. Figure 5 shows that they may outperform SPP in the long run.
Figure 5: Separations obtained using a second-generation silica monolith column (left) and a superficially porous particle column (right). Columns: (left) 50 mm x 4.6 mm monolith, (right) 50 mm x 4.6 mm, 2.6-µm core–shell; mobile-phase A: 20 mM phosphate buffer, pH 4.5; mobile-phase B: acetonitrile; gradient: 20–40% B in 12 min; flow rate: 1 mL/min; injection volume: 2 µL; detection: UV absorbance at 230 nm. Peaks: 1 = ascorbic acid, 2 = 4-hydroxybenzoic acid, 3 = benzoic acid, 4 = sorbic acid, 5 = methyl-4-hydrobenzoate, 6 = ethyl-4-hydroxybenzoate, 7 = propyl-4-hydroxybenzoate. (Courtesy of Merck Millipore.)
The concluding part of this presentation will briefly look at possible future directions for column technology, including improved monoliths; microbore, capillary, and microfluidic platforms; engineered (ordered) columns via micelle templating with pseudomorphic transformation; pillar arrays; and the potential application of three-dimensional (3D) printing techniques. With regards to selectivity and peak capacity improvements, two-dimensional (2D) (and even 3D column configurations) chromatography has received lots of attention and with modern instrumentation now available, multidimensional techniques may become another daily tool in the liquid chromatographer's arsenal.
For a more detailed expansion of the themes introduced here, please consult references 1, 6, and 7.
(1) R.E. Majors, LCGC North Am. 33(11), 818–840 (2015).
(2) A.J.P. Martin and R.L.M Synge, Biochem. J. 35, 1358–1368 (1941).
(3) R.E. Majors, Anal. Chem. 44, 1722 (1972).
(4) J.J. Kirkland, Anal. Chem. 64, 1239–1245 (1992).
(5) D.S. Bell, LCGC North Am. 33(6), 386–395 (2015).
(6) R.E. Majors, LCGC North Am. "The Best of Column Watch and Sample Prep Perspectives: A Farewell to Ron Majors," 33(s11) (2015).
(7) R.E. Majors, LCGC North Am. 33(12), 886–893 (2015)
Ronald E. Majors
Ronald E. Majors is an analytical consultant in West Chester, Pennsylvania and the recipient of LCGC's 2018 Lifetime Achievement in Chromatography Award.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
Inside the Laboratory: The Richardson Group at the University of South Carolina
November 20th 2024In this edition of “Inside the Laboratory,” Susan Richardson of the University of South Carolina discusses her laboratory’s work with using electron ionization and chemical ionization with gas chromatography–mass spectrometry (GC–MS) to detect DBPs in complex environmental matrices, and how her work advances environmental analysis.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
Infographic: Be confidently audit ready, at any time and reduce failures in pharma QC testing
November 20th 2024Discover how you can simplify the audit preparation process with data integrity dashboards that provide transparency to key actions, and seamlessly track long-term trends and patterns, helping to prevent system suitability failures before they occur with waters_connect Data Intelligence software.
Critical Role of Oligonucleotides in Drug Development Highlighted at EAS Session
November 19th 2024A Monday session at the Eastern Analytical Symposium, sponsored by the Chinese American Chromatography Association, explored key challenges and solutions for achieving more sensitive oligonucleotide analysis.